Cellens Inc
The most accurate non-invasive bladder cancer detection method
* Data source: Crunchbase
- Founded
- 2021
- Employees*
- 2-10
- Funding to Date*
- $500,000
- Website
- cellensinc.com
“Patients hate the invasiveness of cystoscopies. And urologists have more valuable uses of their time. 90% of them can be eliminated with just a urine sample.”
Cellens is at 94% accuracy in detecting bladder cancer from urine. Next up is colorectal, then replacing the PSA score.
Cellens is developing and commercializing a non-invasive urine-based test for cancer-monitoring purposes. Cellens has pioneered label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning. Our novel application of quantitative physical properties analysis in cancer cell detection reveals new clinically meaningful information – and high-performing diagnostic tests.
More Companies
